Abstract
Coronary artery spasm (CAS) remains a significant clinical challenge, often linked to endothelial dysfunction. While statins are known to improve endothelial function, their long-term clinical benefit for CAS patients—particularly those without significant coronary artery stenosis—remains controversial. This protocol outlines a systematic review and meta-analysis designed to evaluate whether statin therapy improves clinical outcomes, such as major adverse cardiovascular events (MACE), in this specific population.
Introduction
Coronary artery spasm (CAS), also known as vasospastic or Prinzmetal’s angina, involves the sudden constriction of coronary arteries. This can lead to severe chest pain, myocardial infarction, or sudden cardiac death. Although calcium channel blockers are the standard treatment, the role of statins as an adjunctive therapy is debated. Statins exhibit pleiotropic effects beyond cholesterol lowering, including the potential to repair the vascular endothelium. However, clinical evidence for their efficacy in CAS is inconsistent.
Problem Statement
The primary cause of CAS is thought to be endothelial dysfunction. While statins are proven to benefit patients with atherosclerotic disease (stenosis), their utility in patients whose primary issue is vasospasm without significant blockages is less clear. Current clinical practice lacks a consensus on whether these patients should be routinely prescribed statins for long-term protection. This study aims to resolve this controversy by synthesizing data from high-quality prospective studies.
Methodology
The proposed systematic review will follow a rigorous, pre-registered protocol to ensure transparency and minimize bias.
Search Strategy and Data Sources
A comprehensive search will be conducted across PubMed, Google Scholar, Embase, and the Cochrane Library. The search strategy utilizes Boolean operators to combine terms related to "vasospastic angina," "Prinzmetal’s variant," and "statin." To ensure completeness, the reference lists of all identified articles will be manually screened.
Inclusion and Quality Assessment
The review will focus exclusively on prospective studies to maintain a high level of evidence. Studies will be excluded if they have incomplete data, research design flaws, or fail to report on Major Adverse Cardiovascular Events (MACE). The quality of the included non-randomized studies will be evaluated using the Newcastle-Ottawa Scale (NOS).
Statistical Analysis
Data synthesis, sensitivity analysis, and subgroup analysis will be performed using Stata software. Subgroup analyses will specifically investigate the impact of statins on various clinical endpoints, including cardiogenic death, myocardial infarction, and the need for revascularization.
Expected Insights and Outcomes
As a protocol, this document establishes the framework for future results. The primary outcomes of interest include:
- Main Outcomes: Cardiogenic death, myocardial infarction, and non-cardiogenic death.
- Secondary Outcomes: Severe arrhythmia, recurrent angina pectoris, and the requirement for revascularization.
The study aims to bridge the gap between the known biological mechanisms of statins and actual clinical survival rates. By focusing on patients without severe stenosis, the researchers hope to identify whether the "pleiotropic" benefits of statins are sufficient to justify their use in non-atherosclerotic CAS.
Limitations and Future Directions
The success of this meta-analysis depends on the quality and availability of published prospective data. Potential limitations include publication bias (where negative results are less likely to be published) and heterogeneity in how different studies define CAS or measure outcomes.
By registering this protocol with INPLASY, the authors commit to a standardized methodology, which is a critical step in providing a definitive recommendation for clinicians treating vasospastic angina. The subsequent execution of this plan will provide much-needed clarity on the long-term management of coronary spasm.
Summary updated